Contemporary use of
guideline‐based
higher potency
P2Y12
receptor inhibitor therapy in patients with
moderate‐to‐high
risk
non‐ST‐segment
elevation myocardial infarction: Results from the Canadian
ACS
reflective
II cross‐sectional
study
2015 ◽
Vol 91
(1079)
◽
pp. 492-496
◽
Keyword(s):
Keyword(s):
2014 ◽
Vol 113
(12)
◽
pp. 2064-2069
◽
2017 ◽
Vol 136
(20)
◽
pp. 1895-1907
◽